← Back to Home

Glaucoma Cell Reprogramming Therapy Reports First Human Data: Three Participants Tolerated Treatment in the Short Term; Dose to Be Increased

ER-100 aims to adjust gene expression in damaged eye cells to restore visual function. The first three participants’ 56-day results support continued progress in the trial, but the visual field improvements seen in two participants remain a long way from establishing efficacy.

By SURL BioNews

Vision damage caused by glaucoma is often difficult to reverse. Restoring function in damaged nerve cells in the eye could open another path for treatment. On October 8, Life Biosciences announced the first human data for its experimental therapy ER-100: three participants with open-angle glaucoma tolerated treatment well during the 56 days after dosing, and two showed preliminary improvements on visual field testing.

This Phase 1 trial uses an open-label design and primarily evaluates safety and tolerability. According to the results released by the company, none of the three participants experienced dose-limiting toxicity, serious adverse events, or adverse events of special interest. Reported adverse events were attributed to the injection procedure, steroids, or pre-existing conditions. These assessments come from the company’s disclosure, and the short-term results remain insufficient to establish overall safety.

ER-100 uses a controlled cell reprogramming strategy. A single intravitreal injection delivers three transcription factors—OCT4, SOX2, and KLF4—into the eye, followed by oral doxycycline to induce their expression for eight weeks. The development goal is to adjust cells’ gene expression patterns and restore the function of retinal ganglion cells, which transmit visual information to the brain.

Administration into the eye also involves immune responses that need to be managed. The trial uses an AAV2 viral vector alongside a tapering course of oral steroids to reduce the risk of inflammation. The initial dose was 2×10¹¹ vector genomes. The data safety monitoring board has recommended increasing it to 6×10¹¹, three times the original dose. This decision supports the next stage of investigation and does not mean that efficacy has been confirmed.

Visual field changes were the most closely watched signal in this disclosure. Humphrey visual field testing measures participants’ ability to detect light at different locations. In each of the two participants who showed improvement, at least 28% of test points improved by more than 4 decibels on day 56. This describes changes in light sensitivity at some test locations and cannot be directly interpreted as a 28% recovery in overall vision.

Longevity.Technology, which reported on the findings the same day, also emphasized that three participants, an open-label design, and 56 days of follow-up cannot establish that cells have regained vitality or that the treatment is effective. Its report used the data released by the company and did not independently reproduce the results. The lack of a control group also makes it difficult to clearly attribute the visual field changes observed so far to ER-100.

The significance of these data is that cell reprogramming is beginning to undergo testing for safety and functional performance in humans. Higher doses, more participants, and longer follow-up will gradually clarify whether the early signals persist and whether delayed risks emerge. Determining whether this approach can truly improve visual function in people with glaucoma will still require more complete, controlled clinical evidence.

References

  1. Life Biosciences
  2. Longevity.Technology